Brokers Issue Forecasts for Medicus Pharma FY2026 Earnings

Medicus Pharma Ltd (NASDAQ:MDCX) – Research analysts at Brookline Capital Markets upped their FY2026 earnings per share (EPS) estimates for Medicus Pharma in a research report issued on Tuesday, March 31st. Brookline Capital Markets analyst K. Raja now forecasts that the company will post earnings per share of ($0.54) for the year, up from their previous forecast of ($1.25). The consensus estimate for Medicus Pharma’s current full-year earnings is ($1.14) per share. Brookline Capital Markets also issued estimates for Medicus Pharma’s FY2027 earnings at ($0.48) EPS.

A number of other equities analysts also recently commented on the company. Weiss Ratings restated a “sell (d-)” rating on shares of Medicus Pharma in a report on Monday, December 29th. D. Boral Capital reiterated a “buy” rating and issued a $27.00 price target on shares of Medicus Pharma in a report on Thursday, March 19th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Medicus Pharma currently has a consensus rating of “Hold” and a consensus target price of $23.50.

Medicus Pharma Stock Performance

Shares of MDCX stock opened at $0.42 on Thursday. Medicus Pharma has a fifty-two week low of $0.37 and a fifty-two week high of $8.94. The firm has a market cap of $10.73 million, a P/E ratio of -0.15 and a beta of -1.58. The business’s 50 day moving average price is $0.92 and its 200-day moving average price is $1.67.

Medicus Pharma (NASDAQ:MDCX) last released its quarterly earnings results on Thursday, March 26th. The company reported ($0.82) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.50).

Institutional Trading of Medicus Pharma

Several large investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new position in shares of Medicus Pharma during the 2nd quarter worth approximately $41,000. HRT Financial LP purchased a new position in shares of Medicus Pharma in the 4th quarter valued at approximately $42,000. Osaic Holdings Inc. boosted its position in shares of Medicus Pharma by 180.0% during the second quarter. Osaic Holdings Inc. now owns 14,000 shares of the company’s stock valued at $42,000 after purchasing an additional 9,000 shares in the last quarter. Commonwealth Equity Services LLC boosted its position in shares of Medicus Pharma by 161.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock valued at $44,000 after purchasing an additional 17,611 shares in the last quarter. Finally, Brave Asset Management Inc. purchased a new stake in Medicus Pharma in the third quarter worth $46,000.

Medicus Pharma Company Profile

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.